BioSpace News Archive

Hepion Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of metabolic dysfunction-associated steatohepatitis, fibrotic diseases, hepatocellular carcinoma, and other chronic diseases, announced additional efficacy data for rencofilstat, its lead drug candidate.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the third quarter ended September 30, 2023, and provided a corporate update.

UNITY Biotechnology, Inc. reported financial results for the third quarter ended September 30, 2023.

INVO Bioscience, Inc. announced financial results for the third quarter ended September 30, 2023 and provided a business update.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

Apollo Medical Holdings, Inc. announced that leadership is participating in the BTIG Digital Health Forum, being held virtually, on Monday, November 20, 2023, including a panel discussion with Brandon Sim, Co-Chief Executive Officer, at 12:00 p.m. PT/3:00 p.m. ET.

ThermoGenesis Holdings, Inc. reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update.

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the third quarter of 2023 ended September 30, 2023.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.

Harrow, a leading U.S. eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2023.